reptides › briefs › the cagrisema titration schedule from the REDEFINE phase 3 trial

the cagrisema titration schedule from the REDEFINE phase 3 trial

the 20-week ladder used in REDEFINE phase 3, pre-approval.

the short answer

  • REDEFINE-1: 22.7% mean weight loss at 68 weeks
  • target: 2.4 mg sema + 2.4 mg cagrilintide weekly
  • failed non-inferiority vs tirzepatide in REDEFINE-4

member brief

member brief. the full analysis is part of premium membership.

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.

reptides.

the independent research peptide wiki

S A B C D F

still loading. if this does not clear, check your connection.